Lakefront Biotherapeutics revenue and financials
€25.96Change from previous close: −1.74%Absolute change: −€0.46
In the fiscal year ended December 2025, Lakefront Biotherapeutics reported revenue of €1.11B (+303.50% year over year). Net income was €320.88M, a net margin of 28.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +303.50%
- 2025 vs 2024
- Net income growth
- +333.15%
- 2025 vs 2024
- Net margin
- 28.9%
- 2024: 26.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 12.1 | 6.5 | 901 | 71.2 | 65.3 | — |
| Cost of revenue | 9.1 | 4.8 | 0.5 | 10.8 | 4.7 | — |
| Gross profit | 3.0 | 1.7 | 900 | 60.3 | 60.6 | — |
| Selling, general and administrative | 7.5 | 35.5 | 2.9 | 46.4 | 18.8 | — |
| Research and development | 25.5 | 31.0 | 108 | 73.9 | 95.3 | — |
| Operating income | -43.5 | -63.7 | 759 | -41.7 | -57.0 | — |
| EBIT | 79.8 | -63.7 | 560 | 2.4 | -101 | — |
| EBITDA | 79.8 | -63.7 | 560 | 2.4 | -101 | — |
| Pre-tax income | 2.0 | 14.0 | 783 | -221 | -104 | — |
| Income tax | 0.1 | 0.1 | 0.7 | -17.5 | 0.0 | — |
| Net income | 2.1 | 14.5 | 782 | -202 | -106 | — |
| Net income to common shareholders | 2.1 | 14.5 | 782 | -202 | -106 | — |
| Basic EPS | — | 0.22 | — | — | — | -2.33 |
| Diluted EPS | — | 0.22 | — | — | — | -2.33 |
| Average shares (basic) | — | 65.9 | — | — | — | 65.8 |
| Average shares (diluted) | — | 65.9 | — | — | — | 65.8 |